Bamco Inc Neurocrine Biosciences Inc Transaction History

Bamco Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $22.9 Million - $28.6 Million	-263,679 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $10.2 Million - $14.4 Million	106,199 Added 67.44%	263,679 $25.4 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $3.99 Million - $6.12 Million	46,912 Added 42.43%	157,480 $19.2 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $5.93 Million - $8.98 Million	78,965 Added 249.87%	110,568 $9.57 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $16,764 - $20,300	200 Added 0.64%	31,603 $2.85 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $25,210 - $45,888	369 Added 1.19%	31,403 $2.24 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $131,905 - $167,883	1,334 Added 4.49%	31,034 $3.82 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $2.24 Million - $3.15 Million	29,700 New	29,700 $2.92 Million

627

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

Stay updated on Bamco Inc with notifications on news.